HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Statin Therapy in Very Old Patients: Lights and Shadows.

Abstract
Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of death worldwide. High levels of total cholesterol-and of low-density lipoprotein cholesterol in particular-are one of the main risk factors associated with ASCVD. Statins are first-line treatment for hypercholesterolemia and have been proven to reduce major vascular events in adults with and without underlying ASCVD. Findings in the literature show that statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged people, but their benefits in older adults are not as well-established, especially in primary prevention. Furthermore, many particularities must be considered regarding their use in old subjects, such as age-related changes in pharmacokinetics and pharmacodynamics, comorbidities, polypharmacy, and frailty, which decrease the safety and efficacy of statins in this population. Myopathy and a possible higher risk of falling along with cognitive decline are classic concerns for physicians when considering statin use in the very old. Additionally, some studies suggest that the relative risk for coronary events and cardiovascular mortality associated with high levels of cholesterol decreases after age 70, making the role of statins unclear. On the other hand, ASCVD are one of the most important causes of disability in old subjects, so cardiovascular prevention is of particular interest in this population in order to preserve functional status. This review aims to gather the current available evidence on the efficacy and safety of statin use in very old patients in both primary and secondary prevention.
AuthorsLidia Cobos-Palacios, Jaime Sanz-Cánovas, Mónica Muñoz-Ubeda, María Dolores Lopez-Carmona, Luis Miguel Perez-Belmonte, Almudena Lopez-Sampalo, Ricardo Gomez-Huelgas, Maria Rosa Bernal-Lopez
JournalFrontiers in cardiovascular medicine (Front Cardiovasc Med) Vol. 8 Pg. 779044 ( 2021) ISSN: 2297-055X [Print] Switzerland
PMID34912868 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2021 Cobos-Palacios, Sanz-Cánovas, Muñoz-Ubeda, Lopez-Carmona, Perez-Belmonte, Lopez-Sampalo, Gomez-Huelgas and Bernal-Lopez.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: